Explore

Trendline Trendline
Johnson Johnson Acquires Firefly Bio for $1 Billion to Enhance Cancer Treatment

Johnson Johnson Acquires Firefly Bio for $1 Billion to Enhance Cancer Treatment

Johnson Johnson Acquires Firefly Bio for $1 Billion to Enhance Cancer Treatment
Trendline Trendline
Johnson Johnson Acquires Firefly Bio to Enhance Oncology Pipeline with Degrader Antibody Conjugate Platform

Johnson Johnson Acquires Firefly Bio to Enhance Oncology Pipeline with Degrader Antibody Conjugate Platform

Johnson Johnson Acquires Firefly Bio to Enhance Oncology Pipeline with Degrader Antibody Conjugate Platform
Trendline Trendline
IDEAYA Biosciences Announces $300 Million Public Offering to Fund Cancer Therapy Development

IDEAYA Biosciences Announces $300 Million Public Offering to Fund Cancer Therapy Development

IDEAYA Biosciences Announces $300 Million Public Offering to Fund Cancer Therapy Development
Trendline Trendline
Roche Expands BTK Drug Portfolio with $2.3 Billion Deal with Nurix

Roche Expands BTK Drug Portfolio with $2.3 Billion Deal with Nurix

Roche Expands BTK Drug Portfolio with $2.3 Billion Deal with Nurix
Trendline Trendline
Tango Therapeutics and Revolution Medicines Achieve 92% Response in Pancreatic Cancer Trial

Tango Therapeutics and Revolution Medicines Achieve 92% Response in Pancreatic Cancer Trial

Tango Therapeutics and Revolution Medicines Achieve 92% Response in Pancreatic Cancer Trial
Trendline Trendline
Roche Expands Oncology Portfolio with $2.3 Billion Nurix Deal for BTK Degrader

Roche Expands Oncology Portfolio with $2.3 Billion Nurix Deal for BTK Degrader

Roche Expands Oncology Portfolio with $2.3 Billion Nurix Deal for BTK Degrader
Trendline Trendline
Tango and Revolution Medicines' Pancreatic Cancer Treatment Shows 92% Response Rate

Tango and Revolution Medicines' Pancreatic Cancer Treatment Shows 92% Response Rate

Tango and Revolution Medicines' Pancreatic Cancer Treatment Shows 92% Response Rate
Trendline Trendline
AbCellera Appoints Dr. Victor Sandor to Board of Directors, Enhancing Leadership in Antibody Discovery

AbCellera Appoints Dr. Victor Sandor to Board of Directors, Enhancing Leadership in Antibody Discovery

AbCellera Appoints Dr. Victor Sandor to Board of Directors, Enhancing Leadership in Antibody Discovery
Trendline Trendline
Diakonos Oncology Presents Promising Glioblastoma Survival Data and Launches Melanoma Study at ASCO

Diakonos Oncology Presents Promising Glioblastoma Survival Data and Launches Melanoma Study at ASCO

Diakonos Oncology Presents Promising Glioblastoma Survival Data and Launches Melanoma Study at ASCO
Trendline Trendline
Onchilles Pharma Begins Clinical Trial for Cancer Treatment N17350

Onchilles Pharma Begins Clinical Trial for Cancer Treatment N17350

Onchilles Pharma Begins Clinical Trial for Cancer Treatment N17350
USA Today USA Today
Breakthrough pancreatic cancer drug nearly doubles survival in trial

Breakthrough pancreatic cancer drug nearly doubles survival in trial

A new drug targets RAS cancer-causing cells in the pancreas, nearly doubling survival rates in clinical trials. Here's how the drug works.
Trendline Trendline
Vycellix to Present Progress on Universal Cell Cancer Therapy at Key International Meetings

Vycellix to Present Progress on Universal Cell Cancer Therapy at Key International Meetings

Vycellix to Present Progress on Universal Cell Cancer Therapy at Key International Meetings